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Tumor protein p53 (TP53) is the most frequently mutated 
gene in cancer1,2. In patients with myelodysplastic syndromes 
(MDS), TP53 mutations are associated with high-risk dis-
ease3,4, rapid transformation to acute myeloid leukemia 
(AML)5, resistance to conventional therapies6–8 and dismal 
outcomes9. Consistent with the tumor-suppressive role of 
TP53, patients harbor both mono- and biallelic mutations10. 
However, the biological and clinical implications of TP53 allelic 
state have not been fully investigated in MDS or any other 
cancer type. We analyzed 3,324 patients with MDS for TP53 
mutations and allelic imbalances and delineated two subsets 
of patients with distinct phenotypes and outcomes. One-third 
of TP53-mutated patients had monoallelic mutations whereas 
two-thirds had multiple hits (multi-hit) consistent with bial-
lelic targeting. Established associations with complex karyo-
type, few co-occurring mutations, high-risk presentation and 
poor outcomes were specific to multi-hit patients only. TP53 
multi-hit state predicted risk of death and leukemic transfor-
mation independently of the Revised International Prognostic 
Scoring System (IPSS-R)11. Surprisingly, monoallelic patients 
did not differ from TP53 wild-type patients in outcomes and 
response to therapy. This study shows that consideration of 
TP53 allelic state is critical for diagnostic and prognostic pre-
cision in MDS as well as in future correlative studies of treat-
ment response.
In collaboration with the International Working Group for 
Prognosis in MDS (Supplementary Table 1), we assembled a 
cohort of 3,324 peridiagnostic and treatment-naive patients with 
MDS or closely related myeloid neoplasms (Extended Data Fig. 1 
and Supplementary Fig. 1). Genetic profiling included conven-
tional G-banding analyses (CBA) and tumor-only, capture-based, 
next-generation sequencing (NGS) of a panel of genes recurrently 
mutated in MDS, as well as genome-wide copy number probes. 
Allele-specific copy number profiles were generated from NGS data 
using the CNACS algorithm7 (see Methods and Code availability). 
An additional 1,120 samples derived from the Japanese MDS con-
sortium (Extended Data Fig. 2) were used as a validation cohort.
To study the effect of TP53 allelic state on genome stability, 
clinical presentation, outcome and response to therapy, we per-
formed a detailed characterization of alterations at the TP53 locus. 
First, we assessed genome-wide allelic imbalances in the cohort of 
3,324 patients, to include arm-level or focal (~3 Mb) ploidy altera-
tions and regions of copy-neutral loss of heterozygosity (cnLOH) 
(Extended Data Fig. 3, Supplementary Figs. 2–4 and Methods). 
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Collectively, 360 (11%) patients had at least one cnLOH region 
and 1,571 (47%) had at least one chromosomal aberration. Among 
these, 329 karyotypes were complex12 and 177 were monosomal13 
(Supplementary Table 2).
Mutation analysis identified 486 putative oncogenic muta-
tions in TP53 at variant allele frequency (VAF) ≥ 2% across 
378 individuals (Supplementary Figs. 5–7 and Methods). Among 
TP53-mutated patients, 274 (72.5%) had a single TP53 mutation, 
100 had two (26.5%) and four (1%) had three. Allelic imbalances 
overlapping the TP53 locus were found in 177 cases. Of these, 98 
were focal deletions or regions of cnLOH detected by NGS only 
(Supplementary Table 3). Approximately half (54%, n = 149) of 
patients with one TP53 mutation had loss of the wild-type allele by 
deletion or cnLOH. In contrast, only 13% (n = 14) of patients with 
more than one TP53 mutation had a concomitant allelic imbalance 
at the TP53 locus (odds ratio (OR) = 7.6, 95% confidence interval 
(CI): 4.1–15.2) (Fig. 1a). By consideration of mutations and allelic 
imbalances, we defined four TP53-mutant subgroups (Fig. 1b): 
(1) monoallelic mutation (n = 125, 33% of TP53-mutated patients); 
(2) multiple mutations without deletion or cnLOH affecting the 
TP53 locus (n = 90, 24%); (3) mutation(s) and concomitant deletion 
(n = 85, 22%); and (4) mutation(s) and concomitant cnLOH (n = 78, 
21%). Additionally, in 24 patients the TP53 locus was affected by 
deletion (n = 12), cnLOH (n = 2) or isochromosome 17q rearrange-
ment (n = 10) without evidence of TP53 mutations (Fig. 1a).
In subgroups 2–4, clonality estimates of co-occurring mutations 
or allelic imbalances supported biallelic targeting of TP53 (Extended 
Data Fig. 4). In a subset of cases, biallelic targeting was validated 
by phasing analysis or sequential sampling (Supplementary Fig. 8). 
Thus, the TP53 mutant subgroups were organized into two states: 
(1) monoallelic TP53 state representing subgroup 1, with one resid-
ual wild-type copy of TP53, and (2) multi-hit TP53 state encom-
passing subgroups 2–4, with at least two TP53 hits in each patient 
and probably no residual TP53. While most multi-hit samples were 
confidently assigned as biallelic, we maintained a conservative 
‘multi-hit’ notation.
Accurate determination of allelic state requires LOH mapping, 
as can be achieved by NGS-based analysis of sequencing panels7 or 
more comprehensive sequencing methods (Supplementary Fig. 4). 
VAF estimates were not sufficient for precise assessment of TP53 
allelic state (Fig. 1c). For example, 19 cnLOH-positive patients 
had TP53 VAF ≤ 50% (median 29%, range 3–49%), showing that 
one-quarter of cnLOH patients would be misassigned as monoal-
lelic on the basis of VAF.
In monoallelic cases, TP53 mutations were enriched for subclonal 
presentation (median VAF = 13%, median sample purity = 86%) as 
compared to TP53 mutations from patients with multiple mutations, 
which were predominantly clonal (median VAF = 32%, median 
sample purity = 85%) (Fig. 1c). Thus TP53 allelic state—and, by 
extension, whether a wild-type TP53 allele is retained—points 
toward different evolutionary trajectories or potential for clonal 
dominance. Overall, the spectrum of TP53 mutations was shared 
among the two allelic states (Fig. 1d and Supplementary Fig. 9). Of 
note, truncating mutations were enriched in the multi-hit state (28 
versus 14%, OR = 2.3, 95% CI: 1.3–4.2) while hotspot mutations 
accounted for 25% of mutations in the monoallelic state and 20% 
in the multi-hit state.
We next assessed profiles of genome stability and patterns of 
co-mutations for each TP53 state. The correlation between TP53 
mutations and chromosomal aneuploidies is well established3,7,14–16. 
Overall, 67% (n = 252) of TP53-mutated cases had at least two chro-
mosomal deletions as compared to 5% (n = 158) of wild-type cases 
(OR = 35, 95% CI: 27–46). Excluding chr17 (which is linked to state 
definition), there was a significantly higher number of chromosomal 
aberrations per patient in all multi-hit TP53 subgroups compared 
to the monoallelic group (Fig. 2a and Extended Data Fig. 5), and 
this enrichment was most pronounced for deletions (median four 
in multi-hit versus one in monoallelic state). In particular, deletion 
of 5q was observed in 85% of multi-hit patients as opposed to 34% 
of monoallelic patients (OR = 10, 95% CI: 6.1–18; Supplementary 
Fig. 10). Taken together, we found a median of six unique chromo-
somes with aberrations in the multi-hit state and one in the mono-
allelic state (two-sided Wilcoxon rank-sum test W statistic = 2,395, 
P = 1.2 × 10−41; Fig. 2b). Our data suggest that residual wild-type 
TP53 is critical to the maintenance of genome stability, and that the 
association between TP53 and complex karyotype is specific to the 
multi-hit state (91 versus 13% complex karyotype patients within 
multi-hit or monoallelic states, OR = 70, 95% CI: 34–150; Fig. 2c).
The total number of oncogenic gene mutations and the pattern of 
co-mutations were also different among the allelic states. Excluding 
TP53, the number of driver mutations was higher in the monoal-
lelic state compared to the multi-hit TP53 subgroups (Fig. 2d). 
Overall, 40% (n = 102) of multi-hit patients did not have any iden-
tifiable driver mutations other than TP53, while 90% (n = 112) 
of monoallelic patients had at least one other driver mutation 
and 50% (n = 62) had at least three. Differences in the pattern of 
co-mutations were also identified, whereby monoallelic patients 
were significantly enriched for mutations in TET2, SF3B1, ASXL1, 
RUNX1, SRSF2, JAK2, BCOR and CBL (Fig. 2e).
Previous studies have recurrently linked TP53 mutations to 
high-risk presentation (complex karyotype, elevated blasts, severe 
thrombocytopenia) and adverse outcomes3,4. These correlations 
were recapitulated in our study (Supplementary Fig. 11). However, 
the clinical implications of the allelic state have not been investi-
gated. In our cohort, monoallelic TP53 patients were less cytopenic 
(Fig. 3a–c) and had lower percentages of bone marrow blasts com-
pared to multi-hit patients (median 4 versus 9%; Fig. 3d). There 
was a higher prevalence of lower-risk MDS in monoallelic patients, 
while the multi-hit state was enriched for higher-risk WHO (World 
Health Organization) subtypes and poor/very poor IPSS-R cate-
gories (Extended Data Fig. 6a,b). Overall survival (OS) and AML 
transformation were significantly different between the TP53 allelic 
states. In multi-hit state, the median OS was 8.7 months (95% CI: 
7.7–10.3) whereas it was 2.5 years (95% CI: 2.2–4.9) for monoallelic 
patients (hazard ratio (HR) = 3.7, 95% CI: 2.7–5.0, P = 2 × 10−16, 
Wald test). In comparison, wild-type patients had a median OS 
of 3.5 years (95% CI: 3.4–3.9) (Fig. 3e). The effect of monoal-
lelic TP53 on OS was not confounded by del(5q) (Supplementary 
Fig. 12). The 5-year cumulative incidence of AML transformation 
in the multi-hit and monoallelic states was, respectively, 44 and 
21% (HR = 5.5, 95% CI: 3.1–9.6, P = 5 × 10−9, Wald test) (Fig. 3f). 
Of note, all subgroups (more than one gene mutation, mutation 
and deletion, mutation and cnLOH) in multi-hit state had equally 
dismal outcomes (Extended Data Fig. 7a,b). The OS distinction of 
the two states was significant across WHO classes and IPSS-R risk 
groups (Extended Data Fig. 6c,d and Supplementary Fig. 13), and 
multi-hit TP53 identified patients with poor survival across IPSS-R 
strata. Because 10% of multi-hit patients were classified as IPSS-R 
risk very good to intermediate, this shows that assessment of TP53 
allelic state is critical to identification of patients with high-risk dis-
ease. In fact, multivariable Cox proportional hazards models that 
included TP53 state alongside age of diagnosis, cytogenetic risk 
score12 and established predictive features identified multi-hit TP53 
as an independent predictor for the risk of death and AML trans-
formation (HROS = 2.04, 95% CI: 1.6–2.6, P = 5 × 10−8; HRAML = 2.9, 
95% CI: 1.8–4.7, P = 7 × 10−6, Wald test), whereas monoallelic TP53 
state was not different compared to wild-type TP53 (Fig. 3g,h). 
We also evaluated that multi-hit TP53 and complex karyotype, 
but not monoallelic TP53, are independent predictors of adverse 
outcome (Supplementary Fig. 14), emphasizing the importance of 
mapping TP53 state alongside complex karyotype for accurate risk 
estimation.
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Outcomes of monoallelic patients significantly differed with 
the number of co-occurring driver mutations (Fig. 2d,e and 
Supplementary Fig. 15). For example, the 5-year survival rate of 
monoallelic patients with no other identifiable mutations was 81% 
while it was 36% for patients with one or two other mutations, 26% 
for patients with three or four other mutations and 8% for patients 
with more than five other mutations. Contrastingly, the outcome of 
multi-hit patients was not dependent on the number of additional 
mutations, and the 5-year survival rate was uniformly <6%. Taken 
together, multi-hit TP53 patients had few co-mutations and very 
poor survival irrespective of genetic context. Patients with monoal-
lelic TP53 mutations frequently had several co-occurring mutations 
that shaped disease pathogenesis and outcomes. These data further 
showcase that monoallelic TP53 mutations are not independently 
predictive of adverse risk.
In addition to TP53 mutations, TP53 VAF has also been reported 
to be of prognostic significance in MDS17–19. This is probably 
explained by the strong correlation between high VAF and bial-
lelic targeting. Optimal cut-point analysis20 identified that patients 
with monoallelic TP53 mutations and VAF > 22% (n = 38) had 
increased risk of death compared to wild-type patients (HR = 2.2, 
95% CI: 1.5–3.2, P = 0.0001, Wald test), whereas patients with 
monoallelic TP53 mutations and VAF ≤ 22% (n = 87) had OS 
similar to wild-type patients (Extended Data Fig. 7c). This high-
lights that patients with monoallelic mutations and high VAF 
should be closely monitored. It is possible that we missed a second 
TP53 hit in the small subset of monoallelic cases with VAF > 22%. 
Conversely, multi-hit patients had poor outcomes across ranges of 
VAF. Multi-hit patients with VAF ≤ 11% (n = 20) had very dismal 
outcomes, for both OS and AML transformation (Extended Data 
Fig. 7c,d). Importantly, the genomic and clinical associations estab-
lished for multi-hit cases held true irrespective of VAF. Patients with 
multi-hit TP53 had higher genome instability, fewer cooperating 
mutations and more pronounced thrombocytopenia and elevated 
blast counts compared to monoallelic patients in both clonal and 
subclonal ranges (Supplementary Fig. 16). This indicates that, once 
established, a clone with biallelic TP53 targeting exerts its pervasive 
effects on clinical phenotypes and outcomes regardless of its size. 
The determination of TP53 allelic state requires assessment of both 
multiple mutations and subclonal allelic imbalances, and multi-hit 
TP53 state identified very-high-risk patients independently of the 
VAF of TP53 mutations.
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Fig. 1 | Integration of TP53 mutations and allelic imbalances at the TP53 locus identifies TP53 states with evidence of mono- or biallelic targeting.  
a, Number of patients (from patients with any hit at the TP53 locus) with 0, 1, 2 or 3 TP53 mutations. Colors represent the status of chromosome 17 at 
the TP53 locus, to include cnLOH, deletion (del), isochromosome 17q rearrangement (iso17q), gain or no detected aberration (normal). Unbalanced 
translocations leading to 17p deletion are encoded as ‘del’. b, Frequency of TP53 subgroups within TP53-mutated patients. TP53 subgroups are defined as 
cases with (1) single gene mutation (1mut); (2) several mutations with normal status of chromosome 17 at the TP53 locus (>1mut); (3) mutation(s) and 
chromosomal deletion at the TP53 locus (mut + del); and (4) mutation(s) and cnLOH at the TP53 locus (mut + cnLOH). c, Density estimation of VAF of 
TP53 mutations across TP53 subgroups (from top to bottom, 1mut, >1mut, mut + del, mut + cnLOH). d, Distribution of TP53 mutations along the gene body. 
Mutations from patients with monoallelic TP53 are depicted at the top and those from patients with multiple TP53 hits at the bottom. Missense mutations 
are shown as green circles. Truncated mutations corresponding to nonsense or nonstop mutations, frameshift deletions or insertions and splice site variants 
are shown as pink circles. Other types of mutations to include in-frame deletions or insertions are shown as orange circles. TAD, transactivation domain; 
OD, oligomerization domain.
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The emergence of data in support of dominant negative effect 
(DNE)21,22 and gain of function (GOF)23–25 led us to test whether 
outcomes differed based on the nature of the underlying lesion—
that is, missense, truncated or hotspot TP53 mutations. In the 
multi-hit state, no differences were observed for genome instability 
and outcomes across mutation types (Extended Data Fig. 8 and 
Supplementary Fig. 17a,b), indicating that it is the loss of both 
wild-type copies of TP53 that drives the dismal outcomes of 
TP53-mutated MDS patients rather than the underlying mutation 
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Fig. 2 | TP53 allelic state correlates with contrasting levels of genome stability and patterns of co-mutation. a, Number of chromosomal aberrations per 
patient on chromosomes other than 17 across TP53 subgroups (1mut, >1mut, mut + del and mut + cnLOH, with 125, 90, 85 and 78 patients, respectively) 
and types of aberrations—rearrangement (rearr), gain or deletion (del). In all boxplots, the median is indicated by the horizontal line and the first and 
third quartiles by the box edges. The lower and upper whiskers extend from the hinges to the smallest and largest values, respectively, no further than 
1.5× interquartile range from the hinges. ****P < 0.0001, two-sided Wilcoxon rank-sum test, each compared to the same aberration within the 1mut 
group. b, Number of unique chromosomes other than 17 affected by a chromosomal aberration (rearr, gain or del) per TP53 subgroup for 1mut (n = 125), 
>1mut (n = 90), mut + del (n = 85) and mut + cnLOH (n = 78). Dots represent the median across patients and lines extend from first to third quartiles. 
****P < 0.0001, two-sided Wilcoxon rank-sum test, compared to the 1mut group. Wilcoxon W statistic= 9,950, 10,040 and 9,239 and P = 2 × 10−22, 
2 × 10−28 and 1 × 10−27 for >1mut, mut + del and mut + cnLOH, respectively. c, Interaction between TP53 allelic state and complex karyotype; 13% (16/125) 
of monoallelic TP53 patients (1mut) had a complex karyotype and 91% (231/253) of multi-hit TP53 patients (multi) had a complex karyotype. d, Number 
of driver mutations on genes other than TP53 per TP53 subgroup of 1mut (n = 125), >1mut (n = 90), mut + del (n = 85) and mut + cnLOH (n = 78). Dots 
represent the median across patients and lines extend from first to third quartiles. ****P < 0.0001, two-sided Wilcoxon rank-sum test compared to the 
1mut group. W = 8,515, 8,499 and 7,785 and P = 6 × 10−1, 6 × 10−14 and 3 × 10−13 for >1mut, mut + del and mut + cnLOH, respectively e, Proportion of cases 
per TP53 allelic state with driver mutations in genes most frequently co-mutated with TP53. Genes mutated in at least 5% of monoallelic (n = 125) or 
multi-hit (n = 253) patients are represented. ***P < 0.001, **P < 0.01, *P < 0.05, two-sided Fisher’s exact test with Benjamini–Hochberg multiple testing 
correction.
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binding domain (DBD) had no effect on patient outcomes com-
pared to wild-type TP53. However, there was an increased risk of 
death in monoallelic patients with hotspot mutation at amino acid 
positions R175 and R248 (but not R273) compared to wild-type 
patients (HR = 2.3, 95% CI: 1.2–4.7, P = 0.02 for R248 and HR = 3.0, 
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Fig. 3 | TP53 allelic state associates with distinct clinical phenotypes and shapes patient outcomes. a–d, Boxplots indicating the levels of cytopenia, that 
is, hemoglobin (a), platelets (b), absolute neutrophil count (ANC) (c) and percentage of bone marrow blasts (d) per TP53 allelic state of wild-type TP53 
(WT, n = 2,922), monoallelic TP53 (1mut, n = 125) or multiple TP53 hits (multi, n = 253). In all boxplots, the median is indicated by the horizontal line and 
the first and third quartiles by the box edges. The lower and upper whiskers extend from the hinges to the smallest and largest values, respectively, no 
further than 1.5× interquartile range from the hinges. The y-axis values are square-rooted. ****P < 0.0001, ***P < 0.001, two-sided Wilcoxon rank-sum test. 
e,f, Kaplan–Meier probability estimates of overall survival (e) and cumulative AMLt (f) per TP53 allelic state. The numbers of cases with outcome data per 
allelic state are indicated in parentheses. P values are derived from two-sided log-rank and Gray’s tests. g, Results of Cox proportional hazards regression 
for overall survival (OS) performed on 2,719 patients with complete data for OS and with 1,290 observed deaths. Explicative variables are hemoglobin, 
platelets, ANC, bone marrow blasts, cytogenetic IPSS-R risk scores (very good, good, intermediate (the reference), poor and very poor) and TP53 allelic 
state (monoallelic, multi-hit and wild-type is the reference). Hemoglobin, platelets, ANC and bone marrow blasts are scaled by their sample mean; age 
is scaled by a factor of 10; the x-axis is log10 scaled. Dots and lines represent the estimated hazard ratios and 95% confidence intervals (CI), respectively. 
****P < 0.0001, ***P < 0.001, **P < 0.01, NS, not significant. P > 0.05, Wald test. h, Results of cause-specific Cox proportional hazards regression for 
AMLt performed on 2,464 patients with complete data for AMLt and with 411 observed transformations. Covariates are as in g. Dots and lines represent 
estimated hazard ratios and 95% CI, respectively. ****P < 0.0001, **P < 0.01, NS, not significant, P > 0.05, Wald test.
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Fig. 17c,d), consistent with either DNE21 or GOF25 of the hotspot 
mutant proteins. This suggests that DNE21 may not be applicable to 
all DBD mutations, especially in the setting of MDS where exposure 
to genotoxic therapy is not common. Larger datasets and functional 
studies are warranted to further investigate the operative mecha-
nisms of DBD mutations in MDS.
Beyond primary MDS, TP53 mutations are enriched in 
therapy-related MDS (t-MDS)6,26 and are associated with a high 
risk of progression to AML5. In t-MDS and at progression, 
TP53-mutated patients demarcate an extremely adverse prognostic 
group with a chemorefractory disease and <2% 5-year survival15,16. 
Our cohort included 229 t-MDS cases, with a higher proportion 
of TP53-mutated patients relative to de novo MDS (18 versus 6%, 
OR = 3.3, 95% CI: 2.4–4.6). TP53-mutated t-MDS patients more 
frequently had multiple hits compared to TP53-mutated de novo 
patients (84 versus 65%, OR = 2.8, 95% CI: 1.4–6.6). Comparison 
of genome profiles (Supplementary Fig. 18) and clinical outcomes 
(Fig. 4a) between allelic states reiterated observations from de novo 
MDS. TP53-mutant t-MDS is considered one of the most lethal 
malignancies with limited treatment options27, yet monoallelic 
patients had lower risk of death compared to multi-hit patients 
(HR = 0.39, 95% CI: 0.15–1.0, P = 0.05, Wald test).
To evaluate the effect of TP53 state in disease progression, we 
analyzed serial data from an independent cohort of 12 patients with 
MDS28,29 (St James’s University Hospital, United Kingdom) who 
progressed to AML with a TP53 mutation (Supplementary Fig. 19). 
In 7/12 patients, multiple hits were observed at the time of MDS 
diagnosis, with a 4-month median to AML progression (Supplemen-
tary Fig. 19a–g). In three patients, biallelic targeting occurred dur-
ing disease progression with interclonal competition and attainment 
of clonal dominance for the TP53 clone (Supplementary Fig. 19h,i). 
The remaining two cases that progressed with a monoallelic TP53 
mutation had other high-risk mutations in either RUNX1 and KRAS 
or CBL (Supplementary Fig. 19k,l), consistent with the observation 
from our discovery cohort that monoallelic TP53 mutations tend to 
occur with several and diverse cooperating mutations (Fig. 2d,e). 
These data provided further evidence that biallelic alteration of 
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Fig. 4 | TP53 allelic state demarcates outcomes in therapy-related MDS and on different therapies. a, Kaplan–Meier probability estimates of overall 
survival per TP53 allelic state of wild-type TP53 (WT), monoallelic TP53 (1mut) and multiple TP53 hits (multi), and across types of MDS, that is, de novo 
MDS (solid lines) or therapy-related MDS (dashed lines). Among de novo cases, 101 had a monoallelic TP53 mutation (solid orange line), 184 were 
multi-hit TP53 (solid blue line) and 2,552 were TP53 wild-type (solid gray line). Among therapy-related cases, ten had a monoallelic TP53 mutation 
(dashed orange line), 52 were multi-hit TP53 (dashed blue line) and 162 were TP53 wild-type (dashed gray line). Annotated P values are from two-sided 
log-rank tests. b–d, Kaplan–Meier probability estimates of overall survival (OS) following commencement of treatment with HMA (b) or lenalidomide 
for patients with del(5q) (c) or HSCT (d) per TP53 allelic state. OS was measured from the start of treatment or HSCT to the time of death from any 
cause. Patients alive at the last follow-up date were censored at that time. The number of cases with OS data per TP53 state is indicated in parentheses. 
Annotated P values are from two-sided log-rank tests.
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importance of assessing TP53 allelic state at diagnosis and for dis-
ease surveillance.
We validated the representation of TP53 allelic states (Supple-
mentary Fig. 20), genome stability profiles (Supplementary Fig. 21) 
and differences in clinical phenotypes (Supplementary Fig. 22) in a 
cohort of 1,120 patients with MDS (Extended Data Fig. 2).
Last, we evaluated the implication of TP53 allelic state in 
response to therapy. Recent studies have reported that TP53 patients 
have poor responses to lenalidomide8 and hematopoietic stem cell 
transplantation (HSCT)6,7, as well as marked but transient responses 
to hypomethylating agent (HMA)30. We conducted an exploratory 
survival analysis by allelic state for patients that received HMA, 
lenalidomide (on the subset with deletion of 5q) and following 
HSCT (Extended Data Fig. 9). For HMA and lenalidomide, patients 
with monoallelic TP53 mutations had evidence of longer survival 
compared to multi-hit patients (Fig. 4b,c). The analysis of our 
HSCT cohort was limited due to its size, yet we observed a trend 
for improved survival of monoallelic patients compared to multi-hit 
patients following HSCT (Fig. 4d). These observations highlight the 
importance of mapping TP53 allelic states in future correlative stud-
ies of response to therapy.
In summary, we have provided a detailed characterization of 
TP53 allelic state in 3,324 patients with MDS, and assessed its 
implication for disease biology, clinical presentation and outcomes. 
Two-thirds of TP53-mutated patients had multiple hits (more than 
one gene mutation, mutation and deletion, mutation and cnLOH), 
consistent with biallelic targeting. The remaining one-third had 
monoallelic mutations with one residual wild-type allele.
We have demonstrated that the multi-hit TP53 state in MDS, 
not the bare presence of any TP53 mutation, underlies established 
associations with genome instability, treatment resistance, dis-
ease progression and dismal outcomes. Multi-hit TP53 identified 
very-high-risk patients independently of IPSS-R, co-occurring 
mutations and clonal representation. Surprisingly, monoallelic 
TP53 patients did not differ from TP53 wild-type patients with 
regard to response to therapy, overall survival and AML progres-
sion. The shift in survival for monoallelic patients with the num-
ber of co-mutations indicates diversity of disease pathogenesis and 
highlights the need for future prognostic models that consider a 
large spectrum of gene mutations.
Different evolutionary trajectories between multi-hit and mono-
allelic patients emerged from our data. In multi-hit state, TP53 
mutations were predominantly in the dominant clone with complex 
karyotypes and few other mutations, reflecting early truncal events 
in MDS pathogenesis. In contrast, monoallelic TP53 mutations were 
frequently subclonal and co-occurred with mutations from a broad 
range of genes, to include genes associated with both a favorable31 
(SF3B1) or poor32 (ASXL1, RUNX1, CBL) prognosis. A limitation of 
our study is that we may have missed a second hit for a small sub-
set of cases, such as balanced rearrangement or aberrant methyla-
tion. However, the systematic differences between monoallelic and 
multi-hit patients across genomic and clinical metrics indicate that 
our definition of TP53 allelic state delineates two biologically and 
clinically relevant groups. In Extended Data Fig. 10, we propose a 
workflow to map TP53 allelic state in routine diagnostic practice.
Our findings imply that diagnostic and prognostic precision 
in MDS requires the assessment of TP53 allelic state. We propose 
that biallelic TP53 should be distinguished from monoallelic TP53 
mutations in future revisions of IPSS-R and in correlative studies of 
treatment response. As the most frequently mutated gene in cancer, 
the representation and effect of TP53 allelic state warrant investiga-
tion across cancer indications.
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Methods
Patient samples. The International Working Group for Prognosis in MDS 
(IWG-PM) cohort originated from 24 MDS centers (Supplementary Table 1) that 
contributed peridiagnosis MDS, myelodysplastic/myeloproliferative neoplasms 
(MDS/MPN) and AML/AML with myelodysplasia-related changes (AML-MRC) 
patient samples to the study. Following quality control (Supplementary Fig. 1), 
3,324 samples were included in the study (Extended Data Fig. 1). The source for 
genomic DNA was either bone marrow or peripheral blood mononuclear cells. The 
median time from diagnosis to sampling was 0 d (first quartile, 0 d; third quartile, 
113 d). The validation cohort consisted of 1,120 samples from the Japanese MDS 
consortium (Extended Data Fig. 2). Samples were obtained with informed consent 
in accordance with the Declaration of Helsinki and appropriate Ethics Committee 
approval from each IWG-PM partner institution.
Clinical data. Diagnostic clinical variables were provided by the contributing 
centers and curated to ensure uniformity of metrics across centers and countries. 
Clinical variables included (1) sex; (2) age at diagnosis; (3) WHO disease subtype; 
(4) MDS type (de novo, secondary or therapy-related); (5) differential blood counts 
to include hemoglobin, platelets, white blood cells, neutrophils and monocytes; 
(6) percentage of bone marrow and peripheral blood blasts; (7) cytogenetic data; 
and (8) risk score as per IPSS-R11. Clinical outcomes included the time of death 
from any cause or last follow-up from sample collection, and the time of AML 
transformation or last follow-up from sample collection.
Cytogenetic data. Conventional G-banding analysis (CBA) data were available 
for 2,931 patients, and karyotypes were described in accordance with the 
International System for Human Cytogenetic Nomenclature33. CBA data were risk 
stratified according to the IPSS-R guidelines12 using both algorithmic and manual 
classification by an expert panel of cytogeneticists.
WHO subtypes. Contributing centers provided the vast majority of disease 
classification as per WHO 2008. A pathology review was performed uniformly 
on the entire cohort, to ensure concordance between disease classification and 
diagnostic variables and to update the classification as per WHO 2016. The cohort 
was representative of all MDS WHO subtypes and included 563 (17%) MDS/MPN 
and 167 (5%) AML/AML-MRC samples (Extended Data Fig. 1).
IPSS-R risk scores. IPSS-R risk scores were uniformly calculated based on both 
IPSS-R cytogenetic risk scores and values for hemoglobin, platelets, absolute 
neutrophil count (ANC) and percentage of bone marrow blasts. All IPSS-R risk 
groups were represented (Extended Data Fig. 1).
Targeted sequencing. Panel design. The panel used for targeted sequencing 
included genes recurrently mutated in MDS, as well as 1,118 genome-wide 
single-nucleotide polymorphism (SNP) probes for copy number analysis, with on 
average one SNP probe every 3 Mb. Bait tiling was conducted at 2×. Baits were 
designed to span all exonic regions of TP53 across all transcripts, as described in 
RefSeq (NM_001276761, NM_001276695, NM_001126114, NM_00112611), and 
included 20-base pair (bp) intronic flanking regions.
Library preparation and sequencing. For library construction, 11–800 ng of genomic 
DNA was used with the KAPA Hyper Prep Kit (Kapa Biosystems, no. KK8504) 
with 7–12 cycles of PCR. After sample barcoding, 10–1,610 ng of each library 
was pooled and captured by hybridization. Captured pools were sequenced with 
paired-end Illumina HiSeq at a median coverage of 730× per sample (range,  
127–2,480×). Read length was either 100 or 125 bp.
We also sequenced 48 samples on the panel with the same sequencing 
conditions used for tumor samples, from the blood of young individuals who did 
not have hematological disease, to help further filtering of sequencing artifacts and 
germline SNPs.
Sequencing was performed in an unmatched setting—that is, without a 
matched normal tissue control per patient—so that variants had to be curated 
accordingly (see Variant calling and filtering for artifacts and germline variants).
Alignment. Raw sequence data were aligned to the human genome (NCBI build 
37) using BWA34 v.0.7.17. PCR duplicate reads were marked with Picard tools 
(https://broadinstitute.github.io/picard/) v.2.18.2. For alignment, we used the 
pcap-core dockerized pipeline v.4.2.1 available at https://github.com/cancerit/
PCAP-core.
Sample quality control. Quality control (QC) of fastq and bam data was 
performed with FastQC (http://www.bioinformatics.babraham.ac.uk/projects/
fastqc/) v.0.11.5 and Picard tools, respectively.
In addition, a number of downstream QC steps were performed, including:
•	 Fingerprinting—that is, evaluation of the similarity between all pairs of sam-
ples, based on the respective genotype on 1,118 SNPs. Duplicate samples were 
excluded from the study.
•	 Evaluation of concordance between patient sex from the clinical data and 
coverage on the sex chromosomes. Discordant cases were discussed with the 
contributing centers to rule out patients with Klinefelter syndrome and filter 
out erroneous samples appropriately.
•	 Evaluation of concordance between CBA data and NGS-derived copy number 
profiles (see Copy number and LOH analysis). A typical discordant case is one 
where CBA reports a given deletion or gain in a high number of metaphases 
and the NGS profile clearly shows other abnormalities not reported by CBA. 
All discordant cases were reviewed by a panel of experts through the IWG 
cytogenetic committee.
Finally, samples that passed QC but were found not to be treatment naive—that 
is, the patient received disease-modifying treatment before sample collection—
were excluded from the study. Supplementary Fig. 1 summarizes the QC workflow.
Variant calling and filtering for artifacts and germline variants. Variants were 
derived from a combination of variant callers. For single nucleotide variants 
(SNVs), we used CaVEMan (http://cancerit.github.io/CaVEMan/) v.1.7.4, Mutect35 
v.4.0.1.2 and Strelka36 v.2.9.1. For small insertions and deletions (indels), we  
used Pindel37 v.1.5.4, Mutect v.4.0.1.2 and Strelka v.2.9.1. VAFs were uniformly 
reported across all called variants using the vafCorrect realignment procedure 
available at https://github.com/cancerit/vafCorrect. All called variants were 
annotated with VAGrENT (https://github.com/cancerit/VAGrENT) v.3.3.0 and 
Ensembl-VEP (https://github.com/Ensembl/ensembl-vep) with Ensembl v.91 and 
VEP release 94.5.
Artifact variants were filtered out based on:
•	 Off-target variants—that is, variants called outside of the panel target regions 
were excluded
•	 Variants with VAF < 2%, <20 total reads or <5 mutant supporting reads were 
excluded
•	 The number of callers calling a given variant and the combination of filters 
(flags) from the triple callers; more specifically:
•	 For SNVs, variants called by CaVEMan with >2 CaVEMan flags (from 
the DTH, RP, MN, PT, MQ, SR, TI, SRP, VUM, SE list) were excluded. 
Variants called only by Strelka and Mutect (but not CaVEMan) were fil-
tered out if they had >0 flags or if the dirprop metric (ratio of number of 
reads on each strand) was <0.44. Variants called only by Mutect (but not 
by CaVEMan or Strelka) were filtered out if they had >0 flags or if dirprop 
was <0.44 or VAF < 5%.
•	 For indels, variants called by all three callers (Pindel, Mutect and Strelka) 
were excluded if they had >3 flags. Variants called by only two callers 
were excluded if they had >2 flags. Variants called only by Pindel were 
filtered out if they had >1 flag or <2 mutant reads on one strand. Variants 
called only by Mutect were filtered out if they had >0 flags or <2 mutant 
reads on one strand.
•	 Recurrence and VAF distribution of the called variants on a panel of 48 normal 
samples 
After prefiltering of artifactual variants, germline SNPs were filtered out by 
consideration of:
•	 VAF density of variants consistent with germline SNP
•	 Presence in the Genome Aggregation Database (gnomAD)38. More specifically, 
variants with a population-based allele frequency (VEP_gnomAD_AF) >0.001 
were excluded (with the exception of a few variants in SH2B3 involved in 
familial thrombocythemia). Variants with a maximum allele frequency across 
the gnomAD populations (VEP_MAX_AF) >0.01 were excluded (with the 
exception of ASXL1 amino acid position G646, which requires specific rescue).
•	 Recurrence in a panel of normals
All remaining probable somatic variants after the above-mentioned filtering 
were manually inspected with Integrative Genomics Viewer39 to rule out residual 
artifacts.
Variant annotation for putative oncogenicity. From the list of probable somatic 
variants, putative oncogenic variants were distinguished from variants of unknown 
significance based on:
•	 Recurrence in the Catalog Of Somatic Mutations in Cancer (COSMIC)40, in 
myeloid disease samples registered in cBioPortal40,41 and in the study dataset
•	 Presence in pan-cancer hotspot databases42,43
•	 Annotation in the human variation database ClinVar44
•	 Annotation in the precision oncology knowledge database OncoKB45
•	 Recurrence with somatic presentation in a set of in-house data derived from 
>6,000 myeloid neoplasms16,32,46
•	 The inferred consequence of a mutation where nonsense mutations, splice site 
mutations and frameshift indels were considered oncogenic in tumor suppres-
sor genes (from COSMIC Cancer Census Genes or OncoKB Cancer Gene List) 
For annotation of oncogenicity of TP53 variants we additionally considered:
•	 Functional annotation in the International Agency for Research on Cancer 
(IARC) TP53 database47
•	 Functional classification TP53 prediction scores using PHANTM48
Supplementary Fig. 5 illustrates the rationale and results of the annotation of 
TP53 variants for putative oncogenicity.
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Copy number and LOH analysis. In addition to CBA, we assessed chromosomal 
alterations based on NGS sequencing data using CNACS7. CNACS enables the 
detection of arm-level and focal copy number changes as well as regions of cnLOH. 
CNACS has been optimized to run in the unmatch setting and uses a panel of 
normals for calibration.
Supplementary Fig. 2 provides examples of characterization of allelic 
imbalances (gains, deletions and regions of cnLOH) using CNACS, with 
concordant copy number change findings between CBA and CNACS, focal 
deletions exclusively detected with CNACS and, as expected, regions of cnLOH 
detected only by CNACS. For genome-wide analysis, we considered CNACS 
segments >3 Mb with minor allele frequency <45% (when 50% represents no 
allelic imbalance). Supplementary Fig. 4 provides examples of characterization of 
allelic imbalances by CNACS and SNP arrays on 21 selected samples, with highly 
concordant findings between the two assays.
In addition to CNACS, we also ran CNVkit49 v.0.9.6 on the study cohort. Because 
CNVkit does not infer allele-specific copy numbers, it does not allow marking 
regions of cnLOH but it estimates copy number changes. The integration of two 
copy number tools increased the specificity and sensitivity of copy number calling.
For 2,931 patients with CBA data we performed a detailed comparison of CBA- 
and NGS-derived copy number results (Supplementary Fig. 3), which showed 
highly concordant findings. Along with the annotation of regions of cnLOH, we 
supplemented the presence of copy number changes on patients when it was clear 
on NGS results but missed by CBA (for example, focal deletions). In 393 patients 
with missing CBA data, we used the NGS results to fully annotate copy number 
changes. Because our NGS assay did not allow the detection of translocations, 
inversions, whole-genome amplification and the presence of marker or ring 
chromosomes, those specific alterations were statistically imputed from other 
molecular markers on these 393 patients.
Complex karyotype. Among 2,931 patients with CBA data, 310 had a complex 
karyotype identified by CBA, where complex karyotype was defined as three or 
more independent chromosomal abnormalities. Among those 2,931 patients, NGS 
results helped to identify complex karyotypes in an additional 15 patients. Among 
the 393 cases with missing CBA data, 13 had a complex karyotype according to 
NGS copy number profiles (Supplementary Fig. 3c). Overall 329 patients had a 
complex karyotype, representing 10% of the study cohort.
Statistics. All statistical analyses were conducted using the R statistical platform 
(https://www.r-project.org/) v.3.6.1. Fisher’s exact test and Wilcoxon rank-sum test 
were used to compare categorical and continuous variables. All statistical tests were 
two-sided. Benjamini–Hochberg multiple testing correction was applied when 
appropriate.
Overall survival. Overall survival was measured from the time of sample collection 
to the time of death from any cause. Patients alive at the last follow-up date were 
censored at that time. Survival probabilities over time were estimated using 
Kaplan–Meier methodology, and comparisons of survival across subgroups 
were conducted using the two-sided log-rank test. Kaplan–Meier estimates were 
computed using the R package survival.
Multivariable models of overall survival were performed with Cox proportional 
hazards regression, using the R package coxph. Hazard ratios and 95% CIs 
were reported for covariates, along with P values from the Wald test. Covariates 
included in the multivariable model of overall survival were age, hemoglobin, 
platelets, ANC, bone marrow blasts, cytogenetic risk group and TP53 allelic state. 
Hemoglobin, platelets, ANC and bone marrow blasts were treated as continuous 
variables and were scaled by their sample mean. Age was treated as a continuous 
variable and was scaled by a factor of ten. Cytogenetic risk group was treated as 
a categorical variable, with the intermediate risk group as the reference group. 
TP53 allelic state was treated as a categorical variable, with the wild-type state as 
the reference group relative to monoallelic and multi-hit groups. Those covariates 
correspond to all covariates included in the age-adjusted IPPS-R model along the 
TP53 allelic state.
AML transformation (AMLt). In univariate analysis of AMLt, time to AMLt was 
measured from the time of sample collection to the time of transformation, with 
death without transformation treated as a competing risk. Patients alive without 
AMLt at the last contact date were censored at that time. Cumulative incidence 
functions were used to estimate the incidence of AMLt using the R package 
cmprsk, and comparisons of cumulative incidence function across subgroups were 
conducted using the two-sided Gray’s test.
Multivariable models of AMLt were performed using cause-specific Cox 
proportional hazards regressions, where patients who did not transform but died 
were censored at the time of death. Hazard ratios and 95% CIs were reported for 
the covariates, along with P values from the Wald test. Covariates included in 
the multivariable model of AMLt were the same as those in the model of overall 
survival described above.
Reporting Summary. Further information on research design is available in the 
Nature Research Reporting Summary linked to this article.
Data availability
Clinical, copy number and mutation data are available at https://github.com/
papaemmelab/MDS-TP53-state. The data underlying Figs. 1–4 are provided as 
Source Data.
Databases used in the study are gnomAD (https://gnomad.broadinstitute.org), 
COSMIC (https://cancer.sanger.ac.uk/cosmic), cBioPortal for Cancer Genomics 
(https://www.cbioportal.org), OncoKB Precision Oncology Knowledge Base 
(https://www.oncokb.org), ClinVar (https://www.ncbi.nlm.nih.gov/clinvar) and the 
IARC TP53 Database (https://p53.iarc.fr).
Code availability
The NGS-based, allele-specific copy number algorithm CNACS7 is available as a 
python toil workflow engine at https://github.com/papaemmelab/toil_cnacs, where 
release v.0.2.0 was used in this study. Source code to reproduce figures from the 
manuscript is available at https://github.com/papaemmelab/MDS-TP53-state.
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Extended Data Fig. 1 | Study cohort characteristics. Table describing the baseline characteristics of the study cohort. 1Q: first quartile; 3Q: third quartile; 
OS: overall survival; #: AML classification per WHO 2016 and previously RAEB-T cases. $: Median follow-up time is calculated for censored patients.
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Extended Data Fig. 2 | Validation cohort characteristics. Table describing the baseline characteristics of the validation cohort. 1Q: first quartile; 3Q: third 
quartile; OS: overall survival; $: Median follow-up time is calculated for censored patients.
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Extended Data Fig. 3 | Landscape of chromosomal aberrations in MDS. a, Landscape of chromosomal arm-level aberrations across 3,324 patients. 
Aberrations include copy-neutral loss of heterozygosity (cnloh), deletion (del) and gain. Chromosomes or chromosome arms with more than 5 aberrations 
are depicted on the x-axis. Aberrations were assessed using the integration of conventional G-banding analysis (CBA) data and NGS derived allele 
specific copy-number profiles (see Methods). NGS aberrant segments were restricted to segments larger than 3 megabases. b, Frequency distribution of 
chromosomal aberrations ordered by type of aberrations. First top three plots represent arm-level copy-neutral loss of heterozygosity (cnloh), deletion 
(del) and gain. Fourth bottom plot represents other types of aberrations to include the presence of marker chromosome (mar), rearrangements where 
r_i_j denotes a rearrangement between chromosome i and j, isochromosome 17q (iso17q), whole genome amplification (WGA) and presence of ring 
chromosome (ring). All aberrations observed in more than 3 patients are depicted. Of note, cnloh is detectable with NGS but not with CBA. On the 
opposite, rearrangements, presence of marker or ring chromosome and WGA were only assessed from CBA data. In 393 cases with missing CBA data, 
those specific aberrations were imputed from other molecular markers.
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Extended Data Fig. 4 | See next page for caption.
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Extended Data Fig. 4 | Evidence of biallelic TP53 targeting in the cases with multiple TP53 hits. a, Scatter plot of the two maximum TP53 variant allele 
frequency (VAF) values from cases with multiple TP53 mutations and no copy-neutral LOH or deletion at TP53 locus (n=90). Points are annotated 
according to the level of information of the mutation pairs. In 67% (n=60) of pairs the sum of the two VAFs exceeded 50% so that the mutations were 
considered to be in the same cells as per the pigeonhole principle (triangle and diamond points). In 18 cases, the genomic distance between two mutations 
was within sequencing read length and it was therefore possible to phase the mutations. In all those cases the mutations were observed to be unphased, 
that is, in trans (square and diamond points). Within those 18 pairs of unphased mutations, 10 pairs had a sum of VAFs above 50%, that is, mutations 
were necessarily on different alleles and in the same cells, implying biallelic targeting (diamond points). b, c, Scatter plots of the VAF of TP53 mutations 
and minor allele frequency of 17p heterozygous SNPs from cases with one TP53 mutation and 17p deletion (b., n=69) or 17p copy-neutral LOH (c., n=61). 
The high correlations in (a.), (b.) and (c.) (R2 of 0.77, 0. 94 and 0.97, respectively) are indicative of biallelic targeting of TP53. d, Table of pairs of TP53 
mutations from the same patients that could be phased. All pairs were in trans, that is, mutations were supported by different alleles. e, Representative IGV 
example of unphased mutations (patient p12 from table (d.)).
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Extended Data Fig. 5 | See next page for caption.
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Extended Data Fig. 5 | Heatmap of chromosomal aberrations per TP53 allelic state. Each column represents a patient from the TP53 subgroups of 
monoallelic mutation (top orange band, 1mut), multiple mutations (top light blue band, >1mut), mutation(s) and deletion (top blue band, mut+del) and 
mutation(s) and copy-neutral loss of heterozygosity (top dark blue band, mut+cnloh). Aberrations observed at a frequency higher than 2% in either 
monoallelic or multi-hit TP53 state are depicted on the y-axis. Aberrations include from top to bottom the annotation of complex karyotype (complex), the 
presence of marker chromosome (mar), deletion (del), gain (plus), rearrangement (with r_i_j rearrangement between chromosome i and j), copy-neutral 
loss of heterozygosity (cnloh), whole genome amplification (WGA) and the presence of ring chromosome (ring). The deletions of 17p of two cases from 
the 1mut TP53 subgroup did not affect the TP53 locus.
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Extended Data Fig. 6 | TP53 allelic state segregates patient outcomes across WHO subtypes and IPSS-R risk groups. a, Proportion of WHO subtypes 
per TP53 allelic state of monoallelic mutation (1mut) and multiple hits (multi). t-MDS: therapy-related MDS; SLD: single lineage dysplasia; RS: ring 
sideroblast; MLD: multiple lineage dysplasia; EB: excess blasts; AML-MRC: AML with myelodysplasia-related changes; U: unclassified. Multi-hit TP53 
is enriched for t-MDS compared to monoallelic TP53 state (21% vs. 8%, OR=2.9, p=0.002 two-sided Fisher exact test) and for MDS-EB2 (31% vs. 
13%, OR=3.1, p=5x10−5 two-sided Fisher exact test). Contrarily, monoallelic TP53 is enriched for MDS-del5q (15% vs. 2%, OR=8.4, p=6x10-6 two-sided 
Fisher exact test). b, Proportion of IPSS-R risk groups per TP53 allelic state. Multi-hit TP53 is strongly enriched for the very-poor category compared to 
monoallelic TP53 state (74% vs. 9%, OR=28, p=2x10-35 two-sided Fisher exact test). c, Kaplan-Meier probability estimates of overall survival (OS) across 
main WHO subtypes per TP53 allelic state of wild-type TP53 (WT), monoallelic TP53 (1mut) and multiple TP53 hits (multi). WHO subtypes MDS-SLD and 
MDS-MLD are merged together as MDS-SLD/MLD and WHO subtypes MDS-EB1 and MDS-EB2 are merged together as MDS-EB1/2. d, Kaplan-Meier 
probability estimates of overall survival across IPSS-R risk groups per TP53 allelic state. IPSS-R very-good and good risk groups are merged together 
(leftmost panel), and IPSS-R very-poor and poor risk groups are merged together as well (rightmost panel). In (c.) and (d.), annotated p-values are from 
two-sided log-rank tests and numbers indicate cases with OS data per allelic state.
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Extended Data Fig. 7 | Outcomes across TP53 subgroups and VAF strata. a, b, Kaplan-Meier probability estimates of overall survival (a.) and cumulative 
incidence of AML transformation (AMLt) (b.) across TP53 subgroups of wild-type TP53 (WT), single TP53 mutation (1mut), multiple TP53 mutations 
(>1mut), TP53 mutation(s) and deletion (mut+del), TP53 mutation(s) and copy-neutral loss of heterozygosity (mut+cnloh). c-d, Kaplan-Meier probability 
estimates of overall survival (c.) and cumulative incidence of AMLt (d.) per TP53 allelic state and range of variant allele frequency (VAF) of TP53 
mutations. Annotated p-values are from two-sided log-rank tests in (a.) and (c.) and from two-sided Gray’s tests in (b.) and (d.). The number of cases with 
outcome data per group is indicated in parentheses.
NATURE MEDICINE | www.nature.com/naturemedicine
LettersNature MediciNe
Extended Data Fig. 8 | Maintained differences in genome instability levels and outcomes between TP53 states per mutation type. a, Proportion of 
different types of mutation per TP53 subgroup. Truncated mutations (pink) include frameshift indels, nonsense or nonstop mutations and splice-site 
variants. Mutations annotated as hotspot (purple) are missense mutations at amino acid positions 273, 248, 220 and 175. Mutations annotated as 
other-missense (green) are additional missense mutations or inframe indels. Odds ratio and two-sided Fisher’s test p-values for the proportion of 
truncated versus non-truncated mutations between the multi-hit TP53 subgroups and the monoallelic TP53 subgroup (1mut) are indicated on the right 
side. b, Number per patient of unique chromosomes other than 17 with aberrations per TP53 subgroup of single gene mutation (1mut), mutation and 
deletion (mut+del) and mutation and copy-neutral loss of heterozygosity (mut+cnloh) and across mutation types. Note that 5 patients with both several 
mutations and deletion or cnloh with ambiguity between the mutation type categories have been excluded for this analysis. The number of patients within 
each category is indicated in parentheses. In boxplots, the median is indicated by the tick horizontal line, and the first and third quartiles by the box edges. 
The lower and upper whiskers extend from the hinges to the smallest and largest values, respectively, no further than 1.5x the interquartile range from 
the hinges. Data beyond the whiskers are plotted individually as dots. The annotated p-values are derived from the two-sided Wilcoxon rank-sum test, 
each compared to the 1mut group within the same mutation type. c. Kaplan-Meier probability estimates of overall survival (OS) per TP53 subgroup across 
mutation types. Annotated p-values are from two-sided log-rank tests. The number of cases per subgroup with OS data is indicated in parentheses.
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Extended Data Fig. 9 | Characteristics of treated cohort subsets. Table describing the baseline characteristics of the subset of patients that i) received 
hypomethylating agent (HMA), ii) received Lenalidomide in the context of del(5q) or iii) underwent hematopoietic stem cell transplantation (HSCT).
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Extended Data Fig. 10 | Clinical workflow for the assessment of TP53 allelic state. Schematic of a simple clinical workflow based on the number of 
TP53 mutations, the presence or absence of deletion 17p per cytogenetic analysis, and the presence or absence of cnLOH or focal deletion at 17p per 
NGS based assay or SNP array. Mutations were considered if VAF≥2%. VAF: variant allele frequency; CK: complex karyotype; OS: overall survival; AML: 
transformation to acute myeloid leukemia.
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toil_cnacs. We also used CNVkit version 0.9.6 (https://cnvkit.readthedocs.io/en/stable/#). 
 
Statistics: 
All statistical analyses were conducted using the R statistical platform (R Core Team 2019) (https://www.r-project.org/) version 3.6.1. Kaplan-
Meir estimates were computed using the "survival" R package, incidence of AML transformation were estimated using the "cmprsk" R 
package and Cox proportional hazards regressions were performed  using the "coxph" R package. 
 
Reproducibility: 
Source code to reproduce analysis is available at https://github.com/papaemmelab/MDS-TP53-state
For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and 
reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.
Data
Policy information about availability of data
All manuscripts must include a data availability statement. This statement should provide the following information, where applicable: 
- Accession codes, unique identifiers, or web links for publicly available datasets 
- A list of figures that have associated raw data 
- A description of any restrictions on data availability
Clinical, copy-number and mutation data are available at https://github.com/papaemmelab/MDS-TP53-state. The data that underlie Fig1-4 are provided as Source 
Data. 
 
Databases used in the study are gnomAD https://gnomad.broadinstitute.org, COSMIC https://cancer.sanger.ac.uk/cosmic, cBioPortal for Cancer Genomics https://
www.cbioportal.org, OncoKB Precision Oncology Knowledge Base https://www.oncokb.org, ClinVar https://www.ncbi.nlm.nih.gov/clinvar and IARC TP53 Database 
https://p53.iarc.fr. 
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Policy information about studies involving human research participants
Population characteristics Covariate population characteristics:  
- Age at diagnosis 
- Time from diagnosis to sample collection 
- Gender 
- Bone marrow blasts count 
- Hemoglobin level 
- Platelet level 
- Neutrophil count 
- Cytogenetic and Cytogenetic risk group 
- IPSS-R risk score 
- Diagnostic WHO 2016 subtype 
- Time from diagnosis to treatment 
- Type of disease modifying treatment received 
- Time from diagnosis to AML transformation 
- Overall survival 
- Vital status
Recruitment All patients with a diagnosis of myelodysplastic syndromes or closely related myeloid neoplasms at any of the partner 
institutions were eligible for and consented for the study. No exclusionary criteria existed. Patient's samples had to be either 
diagnostic or ascertained prior to the patient receiving disease modifying treatments that could alter the molecular and 
clonal inferences.
Ethics oversight Samples were obtained with informed consent in accordance with the Declaration of Helsinki and appropriate ethics 
committee approval from each partner institution. Partner institutions that obtained ethical approval from ethical 
committees are: 
Memorial Sloan Kettering Cancer Center.  
Karolinska Institute. 
Dusseldorf MDS Registry. 
University of Pavia. 
Le Fe University Hospital. 
Radboudumc Medical Center Nijmegen.  
Cochin Hospital. 
Chang Gung Memorial Hospital. 
Gruppo Romano Laziale MDS. 
University of Bologna. 
Medical University of Vienna. 
Hannover Medical School. 
University Hospital Dresden. 
Federal University of Ceara. 
Institut Josep Carreras. 
Aou Careggi Hospital. 
Democritus University of Thrace. 
University of Oxford. 
Hospital Isrealita Albert Enstein. 
Vanderbilt University. 
Institute of Hematology and Blood Transfusion.  
University Medicine Gottingen. 
Rete Hemtologica Lombarda. 
Saint Louis Hospital. 
Note that full information on the approval of the study protocol must also be provided in the manuscript.
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